Marc Blaustein - Sep 8, 2021 Form 4 Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Role
Chief Operating Officer
Signature
/s/ Sydney Gaylin, Attorney-in-Fact
Stock symbol
FNCH
Transactions as of
Sep 8, 2021
Transactions value $
$0
Form type
4
Date filed
9/10/2021, 04:27 PM
Next filing
Feb 28, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FNCH Employee Stock Option (right to buy) Award $0 +150K $0.00 150K Sep 8, 2021 Common Stock 150K $15.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vest on September 8, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.